

- recurrence of, after liver transplantation, 2068, 2074
- risk factors for, 1991, 2014t
- screening for, 882–883, 2013–2014, 2014t
- transfusion-transmitted, 138e-3t, 138e-6
- transmission of, 2012–2013, 2013t
- treatment of, 2020
- urticarial vasculitis in, 363, 363t
- Hepatitis B virus (HBV) vaccine
- adverse effects of, 2218t
- contraindications to, 790t
- liver cancer risk and, 478
- for postexposure prophylaxis, 2021–2022
- recommended administration of
- in adults, 787–788f, 883, 2021, 2022t
- in cancer patients, 485t
- in hemodialysis patients, 2022t
- in HIV infection, 788f, 1252t
- in infants and children, 2021, 2022t
- in liver disease, 1995
- in transplant recipients, 929, 929t
- in travelers, 795, 795t
- Hepatitis B x antigen (HBxAg), 2005f, 2007
- Hepatitis C virus (HCV), 2006t, 2009–2010, 2009f, 2010f
- Hepatitis C virus (HCV) infection
- chronic, **2040**
- alcoholic liver disease associated with, 2052, 2052t, 2725
- aminotransferase activity in, 2041
- cirrhosis due to, 2040–2041, 2059–2060
- clinical features of, 2041
- arthritis, 837
- cardiomyopathy, 1560
- cholestasis, 284
- cryoglobulinemic vasculitis, 2041, 2048, 2180, 2191
- depression, 2714
- lichen planus, 349, 353
- osteosclerosis, 426e-5
- porphyria cutanea tarda, 390
- urticarial vasculitis, 363, 363t
- diagnosis of, 366e-1–3f, 2031t, 2041
- global considerations in, 2059–2060
- iron overload in, 2518
- liver disease progression in, 2040–2041
- prognosis of, 2041
- renal involvement in, 1849
- treatment of, **2041**
- after liver transplantation, 2048
- after relapse or nonresponse, 2048
- antiviral therapy, 2044, 2045–2046t, 2047–2049
- boceprevir, 2044, 2046–2047
- combination therapy, 215e-4t, 215e-6, 215e-10–11, 2041–2043, 2042f
- genotypes and, 2042, 2047–2048
- in HIV infection, 2048–2049
- IFN-alfacon, 215e-4t, 215e-10
- IFN- $\alpha$ , 2041–2042
- investigative agents, 215e-11, 2047
- liver transplantation, 2068
- PEG IFN- $\alpha$ 2a, 215e-4t, 215e-10, 2043–2044, 2043t
- PEG IFN- $\alpha$ 2b, 215e-4t, 215e-10, 2043–2044, 2043t
- PEG IFN and ribavirin, 2041–2042, 2042f
- recommendations for, 2045–2046t, 2047
- in renal failure, 2049
- ribavirin, 215e-4t, 215e-6, 2041–2042
- simeprevir, 215e-5t, 215e-11, 2047
- sofosbuvir, 215e-5t, 215e-10–11, 2047
- telaprevir, 2044, 2046–2047
- clinical features of, 152e-6t, 2013t, 2015–2016
- complications and sequelae of, 2018–2019
- diagnosis of, 150e-7–8, 152e-6t, 480e-1, 1993t, **2017**, 2018t
- epidemiology of, 2013t, 2014–2015
- etiology of. *See* Hepatitis C virus (HCV)
- genetic considerations in, 2011
- global features of, 2014–2015
- in hemophiliacs, 734, 735
- hepatocellular carcinoma and, 214e-7, 544–545, 545t, 550
- HIV infection and, 1258, 2030
- incubation period for, 152e-6t
- KIRs with, 372e-15t
- lymphoid malignancies and, 697
- pathogenesis of, 2011
- prevention of, 2022
- prognosis of, 2018
- recurrent, after liver transplantation, 2068, 2074–2075
- risk factors for, 1991, 2015t
- screening for, 29t, 49, 2015, 2015t
- transfusion-transmitted, 138e-3t, 138e-6
- transmission of, 2013t, 2014–2015
- in transplant recipient, 927
- treatment of, 152e-6t, 2020
- Hepatitis D virus (HDV), 2005f, 2006t, 2008–2009
- Hepatitis D virus (HDV) infection
- chronic, 2031t, **2040**
- clinical features of, 2013t, 2015–2016
- complications and sequelae of, 2018–2019
- diagnosis of, 1993t, 2017
- epidemiology of, 2013t, 2014
- etiology of. *See* Hepatitis D virus (HDV)
- global considerations in, 2014
- HBV infection with, 2011, 2014
- pathology of, 2012
- prevention of, 2022
- prognosis of, 2018
- transmission of, 2013t, 2014
- treatment of, 215e-5t, 2020
- Hepatitis E virus (HEV), 2005f, 2006t, 2010
- Hepatitis E virus (HEV) infection
- clinical features of, 152e-2t, 2013t, 2015–2016
- diagnosis of, 152e-2t, 1993t
- epidemiology of, 152e-2t, 1991, 2013t, 2015
- etiology of. *See* Hepatitis E virus (HEV)
- global considerations in, 1991, 2015
- incubation period for, 152e-2t
- pathology of, 2012
- prevention of, 2022
- prognosis of, 2018
- in returning war veterans, 152e-2t
- risk factors for, 1991
- transmission of, 2013t, 2015
- treatment of, 2020
- Hepatitis G virus (GB virus C) infection, 1258
- Hepatocellular carcinoma (HCC), **544**
- approach to the patient, 547
- biopsy in, 547
- clinical features of, 545–546, 545t
- deaths from, 467t, 469f, 471t, 544
- diagnosis of, 366e-4f, 547, 1993t
- epidemiology of, 544
- etiology of, 102e-2, 214e-7, 544–545, 545t
- fibrolamellar, 552
- global considerations in, 544–545, 544t
- in hemophilia, 735
- hepatitis and, 101e-7, 214e-7, 477t, 544–545, 545t
- history in, 547
- imaging in, 547
- immunopathology of, 372e-25t, 547
- incidence of, 467t, 468, 468f, 471t, 544, 544t
- paraneoplastic syndromes in, 545–546, 609t
- physical examination in, 547
- prevention of, 548
- risk factors for, 544–545, 545t, 2530
- screening for, 547–548
- staging of, 546–547, 546t
- treatment of, 102e-5t, 102e-17, **548**
- adjuvant therapy, 550
- algorithm for, 548f
- chemotherapy, 550
- liver transplantation, 549–550, 2068
- new directions in, 551, 551t
- options for, 549t, 552
- response to, 551–552
- in stages I and II, 548–549, 549t
- in stages III and IV, 550–551, 551t
- targeted chemotherapy, 550–551, 551t
- transhepatic artery chemoembolization, 549, 549t
- tumor markers in, 473t
- Hepatocellular diseases, 1990, 1990t. *See also* Liver disease/failure
- Hepatocyte growth factor/c-Met pathway, 102e-11f
- Hepatocytes, 1990
- Hepatomegaly
- abdominal swelling with, 286
- in *Brucella* infections, 194e-3
- in Gaucher disease, 432e-5
- in heart failure, 1504
- in hepatocellular carcinoma, 545
- in liver disease, 1992
- in lysosomal storage diseases, 432e-5
- in schistosomiasis, 1426f, 1427
- Hepatopulmonary syndrome, 47e-3, 1992
- Hepatorenal syndrome, 1800, 1809–1810, 2066
- Hepatosplenic  $\gamma\delta$  T-cell lymphoma, 135e-3, 708, 1962
- Hepcidin, 398, 630
- Hephaestin, 626
- Heptavalent botulinum antitoxin (HBAT), 261e-9
- HER2 gene mutations
- in breast cancer, 101e-3, 526, 528
- in gastric adenocarcinoma, 534
- in lung cancer, 507t, 509, 509f
- HER2/neu
- in breast cancer, 102e-10, 103e-19, 103e-21, 528
- drug response and, 39t
- in GI-NETs, 562
- Herbal medicines/supplements
- causing increased bleeding, 404, 404t
- drug interactions of, 14e-4, 14e-4t, 43, 44
- hepatotoxicity of, 2030
- nephrotoxicity of, 577, 1804, 1861
- regulation of, 14e-3
- toxicity of, 14e-3–4
- Hereditary coproporphyrria (HCP)
- clinical features of, 2522t, 2531, 2681
- diagnosis of, 2522t, 2531
- genetic considerations in, 2681
- pathophysiology of, 2522f, 2681
- treatment of, 2531, 2681
- unsafe drugs in, 2526, 2527–2529t
- Hereditary elliptocytosis, 81e-4f, 652f, 653, 653t
- Hereditary endotheliopathy, retinopathy, nephropathy, and stroke (HERNs), 2568
- Hereditary hemochromatosis. *See* Hemochromatosis, hereditary
- Hereditary hemorrhagic telangiectasia. *See* Osler-Weber-Rendu syndrome
- Hereditary inclusion body myopathy, 2195–2196
- Hereditary liability to pressure palsy, 434
- Hereditary nephritis, 294
- Hereditary neuralgic amyotrophy, 2678, 2679t
- Hereditary neuropathy(ies). *See* Peripheral neuropathy, hereditary
- Hereditary neuropathy with liability to pressure palsies (HNPP), 2678, 2679t
- Hereditary nonpolyposis colon cancer (HNPCC; Lynch's syndrome)
- clinical features of, 538t
- early interventions for, 450t, 451
- endometrial cancer in, 596
- epigenetic silencing in, 102e-7
- genetic considerations in, 101e-6t, 539
- APC tumor-suppressor gene, 101e-5
- DNA mismatch/repair, 434
- somatic mutational steps, 101e-1, 101e-1f
- genetic testing for, 450t
- ovarian cancer in, 592
- pancreatic cancer risk in, 554
- polyp distribution and characteristics in, 538t
- screening for, 434, 539
- type 2, 592
- Hereditary persistence of fetal hemoglobin, 633, 639
- Hereditary recurrent fever syndromes
- clinical features of, 2213t
- familial cold autoinflammatory syndrome, 372e-8t, 2215